Skip to main content
SpringerLink
Log in

Der Einsatz von BCG beim oberflächlichen Harnblasenkarzinom

  • Conference paper
Blasenkarzinom

  • 420 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 9.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Böhle A, Jocham D (1998) Die intravesikale Immuntherapie mit Bacillus Calmette-Guérin. Fakten, Vergleiche, Ergebnisse. Gustav Fischer, Stuttgart Jena Lübeck Ulm

    Google Scholar 

  • Böhle A, Gerdes J, Ulmer AJ et al. (1990a): Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53

    PubMed  Google Scholar 

  • Böhle A, Nowc C, Ulmer AJ et al. (1990) Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guérin immunotherapy. J Urol 144: 59

    PubMed  Google Scholar 

  • Böhle A, Busemann E, Gerdes J et al. (1992) Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences. In: Brown F, Revillard RP (eds) Developments in biological standardization. Standardization of the immunopharmacology of natural and synthetic immunomodulators. Karger, Basel, p 199

    Google Scholar 

  • Böhle A, Rüsch-Gerdes S, Ulmer AJ et al. (1996) The effect of lubricants on viability of Bacillus Calmette-Guérin (BCG) for intravesical immunotherapy against bladder carcinoma. J Urol 155: 1892

    PubMed  Google Scholar 

  • Böhle A, Müller M, Otto T (2000) Kurzgefaßte Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Urologie — Harnblasenkarzinom. Internet

    Google Scholar 

  • Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169: 90

    PubMed  Google Scholar 

  • Böhle A, Thanhäuser A, Ulmer AJ et al. Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: Evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150: 1932

    Google Scholar 

  • Bubenik J, Perlmann P, Helmstein K. et al. (1970) Immune response to urinary bladder tumors in man. Int J Cancer 5: 39

    PubMed  CAS  Google Scholar 

  • Coe JE, Feldman JD (1966) Extracutaneous delayed hypersensitivity, particularly in the Guinea-Pig bladder. Immunology 10: 127

    PubMed  CAS  Google Scholar 

  • Coley-Nauts H, Fowler GA, Bogatko FH (1953) A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man. Acta Med Scand 276: 5

    Google Scholar 

  • Cutler SJ, Heney NM, Friedell GW (1982) Longitudinal study of patients with bladder cancer: Factors associated with disease recurrence and progression. In: Bonney W, Prout DR (eds) Bladder cancer. Williams and Wilkins, Baltimore, p 35

    Google Scholar 

  • DeHaven JI, Traynelis C, Riggs DR et al. (1992) Antibiotic and Steroid Therapy of Massive Systemic Bacillus Calmette-Guérin Toxicity. J Urol 147: 738

    PubMed  CAS  Google Scholar 

  • Durek C, Rüsch-Gerdes S, Jocham D et al. Interference of modern antibacterials with Bacillus Calmette Guérin viability. J Urol 162: 1959

    Google Scholar 

  • Freund J (1956) The mode of action of immunologic adjuvants. Adv Tuberc Res 7: 130

    Google Scholar 

  • Holmgren I (1935) La tuberculine et le BCG chez les cancéreux. Schweiz Med Wschrift 65: 1203

    Google Scholar 

  • Hölzel D, Altwein JE (1991) Tumoren des Urogenitaltrakts: klinischepidemiologische Fakten. Urologe A 30: 134

    PubMed  Google Scholar 

  • Kurth K-H, Denis LJ, Bouffioux C (1995) Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31 A: 1840

    Google Scholar 

  • Lamm DL (1985) Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 134: 40

    PubMed  CAS  Google Scholar 

  • Lamm DL, Steg A, Boccon-Gibod L et al. (1989) Complications of bacillus Calmette-Guérin immunotherapy: A review of 2602 patients and comparison of chemotherapy complications. In: Debruyne FMJ, Denis LJ, von der Meijden AP (1989) MEORTC Genito-Urinary Group Monograph 6: BCG in superficial bladder cancer. Liss, New York, p 335

    Google Scholar 

  • Lamm DL, DeHaven JI, Shriver J et al. (1990) A randomized prospective comparison of oral versus intravesical and percutaneous Bacillus Calmette-Guérin for superficial bladder cancer. J Urol 144: 65

    PubMed  CAS  Google Scholar 

  • Lamm DL, Riggs DR, DeHaven JI et al. (1991) Reduction of BCG fatal toxicity in mice. J Urol 145[Suppl]: 858

    Google Scholar 

  • Lamm DL, Blumenstein BA, Crissman JD et al. (2000) Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163: 1124

    PubMed  CAS  Google Scholar 

  • Lutzeyer W, Rübben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 127: 250

    PubMed  CAS  Google Scholar 

  • Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180

    PubMed  CAS  Google Scholar 

  • Morales A, Nickel C, Wilson JWL (1992) Dose-response of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. J Urol 147: 1256

    PubMed  CAS  Google Scholar 

  • Pagano F, Bassi P, Milani C et al. (1991) A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? J Urol 146: 32

    PubMed  CAS  Google Scholar 

  • Rübben H, Graf-Dobberstein C, Ostwald R et al. (1990) Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer after complete resection of superficial bladder cancer; Mitomycin C vs. BCG Connaught vs. TUR alone. In: deKernion JB (ed) Immunotherapy of urologic tumours. Churchill Livingstone, New York, p 27

    Google Scholar 

  • Zingg EJ (1982) Maligne Tumoren der Harnblase. In: Hohenfellner R, Zingg EJ (Hrsg) Urologie in Klinik und Praxis. Thieme, Stuttgart, S 520

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HELIOS Agnes Karll Krankenhaus, Am Hochkamp 21, 23611, Bad Schwartau

    A. Böhle

Authors
  1. A. Böhle
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this paper

Cite this paper

Böhle, A. (2005). Der Einsatz von BCG beim oberflächlichen Harnblasenkarzinom. In: Blasenkarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26850-2_5

Download citation

  • DOI: https://doi.org/10.1007/3-540-26850-2_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20504-3

  • Online ISBN: 978-3-540-26850-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation